Real-world considerations regarding the use of the combination of levodopa, carbidopa, and entacapone (Stalevo
COMT inhibitors
Parkinson's disease
dyskinesia
entacapone
levodopa
wearing off
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
26
06
2023
accepted:
22
07
2023
pubmed:
25
7
2023
medline:
25
7
2023
entrez:
25
7
2023
Statut:
ppublish
Résumé
An important aim in long-term levodopa therapy is to prolong the duration of symptomatic efficacy of each dose without increasing peak plasma concentrations above the threshold for the emergence of dyskinesias. One strategy is to enhance levodopa delivery to the brain by co-administering it with inhibitors of peripheral dopa-decarboxylase and catechol-O-methyltransferase (COMT). Levodopa, carbidopa and entacapone (LCE), available in a range of fixed-dose combinations as the branded formulation Stalevo
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-20Subventions
Organisme : Orion Pharma, Espoo, Finland
Informations de copyright
© 2023 The Author. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Hechtner MC, Vogt T, Zollner Y, et al. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord. 2014;20:969-974. doi:10.1016/j.parkreldis.2014.06.001
Fahn S, Oakes D, Shoulson I, et al. Parkinson study group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508. doi:10.1056/NEJMoa033447
Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80:800-809. doi:10.1212/WNL.0b013e318285c0ed
Nagao KJ, Patel NJ. From medications to surgery: advances in the treatment of motor complications in Parkinson's disease. Drugs Context. 2019;8:212592. doi:10.7573/dic.212592
https://www.biospace.com/article/releases/intec-pharma-reports-top-line-phase-3-trial-results-of-accordion-pill-carbidopa-levodopa-in-advanced-parkinson-s-disease-patients/
Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol. 2009;65:443-455. doi:10.1007/s00228-009-0622-y
Kuoppamäki M, Vahteristo M, Ellmén J, Kieburtz K. Pooled analysis of phase III with entacapone in Parkinson's disease. Acta Neurol Scand. 2014;130:239-247. doi:10.1111/ane.12278
Nissinen H, Kuoppamäki M, Leinonen M, Schapira AH. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. Eur J Neurol. 2009;16:1305-1311. doi:10.1111/j.1468-1331.2009.02726.x
Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I, F-01 Study Group. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol. 2001;45:111-118. doi:10.1159/000052104
Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord. 2009;24:541-550. doi:10.1002/mds.22343
Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74:1071-1079. doi:10.1136/jnnp.74.8.1071
Lees A, Tolosa E, Stocchi F, et al. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev Neurother. 2023;23:15-24. doi:10.1080/14737175.2023.2176220
Eggert K, Skogar O, Amar K, et al. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility-an open-label, 6-week study. J Neural Transm. 2010;117:333-342. doi:10.1007/s00702-009-0344-4
Myllylä V, Haapaniemi T, Kaakkola S, et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom study). Acta Neurol Scand. 2006;114:181-186. doi:10.1111/j.1600-0404.2006.00703.x
Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamäki M, Ellmén J. The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations. Eur J Clin Pharmacol. 2012;68:281-289. doi:10.1007/s00228-011-1121-5
Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L. Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. Expert Opin Pharmacother. 2020;21:2265-2278. doi:10.1080/14656566.2020.1806237
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154-165. doi:10.1016/S1474-4422(15)00336-1
Fabbri M, Ferreira JJ, Rascol O. COMT inhibitors in the Management of Parkinson's disease. CNS Drugs. 2022;36:261-282. doi:10.1007/s40263-021-00888-9
https://www.drugs.com/price-guide/ongentys#
https://www.drugs.com/price-guide/stalevo-200
Fox SH, Katzenschlager R, Lim SY, et al. Movement Disorder Society evidence-based medicine committee. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018;33:1248-1266. doi:10.1002/mds.27372
Cereda E, Cilia R, Canesi M, et al. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. J Neurol. 2017;264:1254-1263. doi:10.1007/s00415-017-8523-y
Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with Rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954. doi:10.1016/S0140-6736(05)71083-7
Kuoppamäki M, Sauramo A, Korpela K, et al. Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa. Int J Clin Pharmacol Ther. 2010;48:756-760. doi:10.5414/cpp48756
Polo O, Ylä-Sahra R, Hirvonen K, Karvinen J, Vahteristo M, Ellmén J. Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. Clin Neuropharmacol. 2007;30:335-344. doi:10.1097/WNF.0B013E31805930C2
Park KW, Jo S, Lee SH, et al. Therapeutic effect of levodopa/carbidopa/Entacapone on sleep disturbance in patients with Parkinson's disease. J Mov Disord. 2020;13:205-212. doi:10.14802/jmd.20055
Xie D, Shen Q, Zhou J, Xu Y. Non-motor symptoms are associated with REM sleep behavior disorder in Parkinson's disease: a systematic review and meta-analysis. Neurol Sci. 2021;42:47-60. doi:10.1007/s10072-020-04769-9
Bares M, Kanovský P, Rektor I. Excessive daytime sleepiness and ‘sleep attacks’ induced by entacapone. Fundam Clin Pharmacol. 2003;17:113-116. doi:10.1046/j.1472-8206.2003.00120.x
Nyholm D, Jost WH. Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance. Ther Adv Neurol Disord. 2022;15:17562864221108018. doi:10.1177/17562864221108018